Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186-19.

Brooks, Benjamin Rix; Pioro, Erik P; Katz, Jonathan; Takahashi, Fumihiro; Takei, Koji; Zhang, Jeffrey; Apple, Stephen

Brooks, Benjamin Rix; Pioro, Erik P; Katz, Jonathan; Takahashi, Fumihiro; Takei, Koji; Zhang, Jeffrey; Apple, Stephen.

Afiliação

Brooks BR; Atrium Health Neurosciences Institute, Carolinas Medical Center, University of North Carolina School of Medicine - Charlotte Campus, North Carolina, USA.
Pioro EP; Neuromuscular Division, Davee Department of Neurology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Katz J; Department of Neurology, Forbes Norris MDA/ALS Center, California Pacific Medical Center, San Francisco, California, USA.
Takahashi F; Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
Takei K; Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan.
Zhang J; Princeton Pharmatech, Princeton, New Jersey, USA.
Apple S; Mitsubishi Tanabe Pharma America, Inc, Jersey City, New Jersey, USA.

Muscle Nerve ; 65(2): 180-186, 2022 02.

Article em En | MEDLINE | ID: mdl-34816454

Assuntos

Esclerose Lateral Amiotrófica; Esclerose Lateral Amiotrófica/tratamento farmacológico; Método Duplo-Cego; Edaravone/uso terapêutico; Humanos; Qualidade de Vida; Inquéritos e Questionários

Palavras-chave

ALSFRS-R item scores; clinical trials; disease progression; functional decline; gross motor function

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Esclerose Lateral Amiotrófica Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google